LAKE FOREST, Ill. -- Hospira, Inc. and its employees announced that they are contributing $300,000, as well as product donations, to support the relief efforts related to last weekend's earthquake and tsunamis affecting southern Asia and the eastern coast of
Africa. Hospira also will match financial contributions from its employees to support relief efforts, up to $50,000.
"The Hospira family expresses deep sympathy to all those affected by this
terrible tragedy," said Christopher B. Begley, chief executive officer,
Hospira. "Hospira is committed to our global community, and we hope that our
donations will help restore health and wellness to this devastated region."
Hospira contributed a $250,000 cash grant to the American Red Cross
International Response Fund and a $50,000 cash grant to AmeriCares, a leading
non-profit aid organization, to support their efforts for this tragedy.
In addition, Hospira donated over 29,000 pounds of medical products via
AmeriCares. Hospira's donation included a variety of intravenous (I.V.)
solutions and injectable drugs, as well as sterile water. Hospira's products
are being included in AmeriCares airlifts to aid disaster survivors in Sri
Lanka, India and Indonesia.
Hospira, Inc. is a global specialty pharmaceutical and medication delivery
company dedicated to Advancing Wellness by developing, manufacturing and
marketing products that help improve the safety and efficacy of patient care.
Created from the core global hospital products business of Abbott
Laboratories, Hospira is a new company with 70 years of service to the
hospital industry. The company's portfolio includes one of the industry's
broadest lines of generic acute-care injectables, which help address the high
cost of proprietary pharmaceuticals in hospitals; integrated solutions for
medication management and infusion therapy; and a full-service contract
manufacturing business.
Source: Hospira, Inc.
Robust infectious disease surveillance, including rapid subtyping of influenza A, is essential for early detection, containment, and public health reporting of novel viral threats.